Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xoma ( (XOMA) ) has provided an announcement.
On February 6, 2026, XOMA Royalty completed a tender offer to acquire approximately 70% of Generation Bio’s outstanding common shares at $4.2913 per share in cash plus one non‑tradeable contingent value right per share. The offer expired one minute after 11:59 p.m. Eastern Time that day, with all conditions satisfied or waived and all validly tendered shares accepted for payment.
XOMA Royalty finalized the acquisition on February 9, 2026, by merging its subsidiary XRA 7 Corp. into Generation Bio under Delaware’s Section 251(h), making Generation Bio a wholly owned subsidiary. At the merger’s effective time, remaining eligible shares were converted into the same cash-and-CVR consideration, while in-the-money options were cashed out and out-of-the-money options cancelled, consolidating full ownership and simplifying the capital structure for XOMA’s expanded biotech royalty platform.
The most recent analyst rating on (XOMA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
Overall score reflects mixed financial performance (strong margins but elevated leverage and weak cash-flow trends) as the primary driver, with neutral technical signals and a high P/E weighing on the outlook; positive corporate developments provide a modest offset.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
XOMA Royalty Corporation operates as a royalty aggregation company, acquiring interests in biopharmaceutical assets and related payment streams. Its portfolio strategy focuses on securing income tied to drug development and commercialization, positioning the company as a specialized player in the life sciences financial ecosystem rather than a traditional drug developer.
Generation Bio Co. is a Delaware-incorporated biotechnology company focused on genetic medicine, with its common stock previously publicly traded. By acquiring Generation Bio, XOMA Royalty deepens its exposure to innovative therapeutic platforms, likely enhancing its long-term royalty and milestone revenue potential within the biotech and genomic medicine space.
Average Trading Volume: 369,173
Technical Sentiment Signal: Sell
Current Market Cap: $307.8M
For detailed information about XOMA stock, go to TipRanks’ Stock Analysis page.